These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 31846222)

  • 1. A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).
    Chen L; Liu X; Li M; Wang S; Zhou H; Liu L; Cheng X
    Cancer Med; 2020 Feb; 9(3):988-998. PubMed ID: 31846222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
    Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
    BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
    Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
    Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry.
    Mattes MD; Lee JC; Metzger DJ; Ashamalla H; Katsoulakis E
    J Gynecol Oncol; 2015 Jan; 26(1):19-24. PubMed ID: 25310855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive lymphadenectomy and survival prediction in uterine serous cancer patients after surgery: A population-based analysis.
    Li H; Xie X; Liu Y; Huang X; Lin H; Li J; Lin Z
    Eur J Surg Oncol; 2020 Jul; 46(7):1339-1346. PubMed ID: 32402510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.
    Huang CY; Tang YH; Chiang YC; Wang KL; Fu HC; Ke YM; Lau HY; Hsu KF; Wu CH; Cheng WF
    Gynecol Oncol; 2014 May; 133(2):221-8. PubMed ID: 24556064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?
    Kwon JS; Abrams J; Sugimoto A; Carey MS
    Int J Gynecol Cancer; 2008; 18(4):820-4. PubMed ID: 17892450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
    Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
    Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen.
    Lee LJ; Demaria R; Berkowitz R; Matulonis U; Viswanathan AN
    Gynecol Oncol; 2014 Jan; 132(1):65-9. PubMed ID: 24211401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
    Sood BM; Jones J; Gupta S; Khabele D; Guha C; Runowicz C; Goldberg G; Fields A; Anderson P; Vikram B
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):208-16. PubMed ID: 12909235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
    Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
    Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
    Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
    J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
    Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.
    Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG
    Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
    Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
    Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
    Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
    Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
    Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
    Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy].
    Xue DB; Ding LJ; Xia AL; Chen D; Xia HP; Teng XD; Xu ST; Zhang SJ; Ren XC
    Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):671-4. PubMed ID: 21176532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Treatment of Uterine Serous Cancer in the Medicare Population.
    Rauh-Hain JA; Connor SC; Clemmer JT; Foley OW; Clark RM; Hall TR; Boruta DM; Schorge JO; del Carmen MG
    Int J Gynecol Cancer; 2015 Jul; 25(6):1023-30. PubMed ID: 25914960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in surgical stage I uterine papillary serous carcinoma.
    Havrilesky LJ; Secord AA; Bae-Jump V; Ayeni T; Calingaert B; Clarke-Pearson DL; Berchuck A; Gehrig PA
    Gynecol Oncol; 2007 Jun; 105(3):677-82. PubMed ID: 17355889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.